Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on May 8, 2025

Draganfly Announces First Quarter Results of 2025
Vancouver, BC., May 08, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its first quarter …

Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on …

Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and …

BioSyent Schedules First Quarter Earnings Release for May 15, 2025
MISSISSAUGA, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2025 on Thursday, May 15, 2025 after market hours. A presentation …

Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter …

Theriva Biologics Announces Closing of $7.5 Million Public Offering
ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, …

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson’s disease in Q4 2025 Strengthened balance sheet with recent financing Advancing innovative POZ Platform across multiple therapeutic modalities Two new seasoned …

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results …

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025 Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for …

PacBio Announces First Quarter 2025 Financial Results
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results: Q1 2025 Q1 2024 Revenue $37.2 million $38.8 million Instrument revenue $11.0 million …

Rackspace Technology Reports First Quarter 2025 Results
Revenue of $665 million in the First Quarter, down 4% Year-over-Year Private Cloud Revenue was $250 million, down 7% Year-over-Year Public Cloud Revenue was $416 million, down 2% Year-over-Year First Quarter 2025 Cash Flow From Operating Activities was $13 …

Turtle Beach Corporation Announces Growth in Revenue, Adjusted EBITDA and Gross Margins in First Quarter 2025 Results and $75 Million Share Repurchase Program
–Net Revenue of $63.9 million, up 14% compared to prior year– –Gross Margin improved to 36.6%, an increase of approximately 470 basis points compared to prior year– –Net Loss of $(0.7) million compared to Net Income of $0.2 million in prior year– –Adjusted …

Microchip Technology Announces Quarterly Cash Dividend on Common Stock of 45.5 Cents Per Share
CHANDLER, Ariz., May 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that its Board of Directors declared a quarterly cash …

Microchip Technology Announces Financial Results For Fourth Quarter and Fiscal Year 2025
For the quarter ended March 31, 2025 Net sales of $970.5 million, declined 5.4% sequentially and 26.8% from the year ago quarter. The midpoint of our guidance provided on February 6, 2025 was net sales of $960.0 million. On a GAAP basis: gross profit of …

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the …

BlackLine Expands Agentic AI Capabilities to Accelerate Future-Ready Financial Operations
LOS ANGELES, May 08, 2025 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) today announced the continued expansion of its artificial intelligence (AI) capabilities, including new agents, delivering on its vision to power future-ready financial operations. …

PubMatic Announces First Quarter 2025 Financial Results; Board of Directors Authorizes $100M Expansion of Share Repurchase Program
Delivered revenue and adjusted EBITDA ahead of guidance; Revenue from omnichannel video, including CTV, grew 20% and was 40% of total revenue; CTV revenue grew over 50% year-over-year; and Supply Path Optimization represented a record 55%+ of total …

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted …

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
Six posters presented at the American Association for Cancer Research (AACR) annual meeting Appointment of Dr. Sabeen Mekan as Senior Vice President, Clinical Development Reported $321.6 million in cash resources as of March 31, 2025 (compared to $324.2 …